ReviewFrontiers in medicine2019
Biologic Treatments in Interstitial Lung Diseases.
Review in Frontiers in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Rituximab for the treatment of connective tissue disease-associated interstitial lung disease: A systematic review and meta-analysis.Frontiers in pharmacology · 2022Pooled it
- Advances in Therapeutics for Chronic Lung Diseases: From Standard Therapies to Emerging Breakthroughs.Journal of clinical medicine · 2025Review
- Pulmonary Diseases in Older Patients: Understanding and Addressing the Challenges.Geriatrics (Basel, Switzerland) · 2024Article
- Mechanisms of Bushenyiqi decoction in the treatment of asthma: an investigation based on network pharmacology with experimental validation.Frontiers in pharmacology · 2024Article
- Transcriptomics in idiopathic pulmonary fibrosis unveiled: a new perspective from differentially expressed genes to therapeutic targets.Frontiers in immunology · 2024Article
- Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.Respiratory research · 2023Article
- Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis.American journal of physiology. Cell physiology · 2023Review
- Treating Autoimmune-Related Interstitial Lung Disease With B Cell Depletion.Frontiers in medicine · 2022Review
- Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break.Frontiers in medicine · 2022Article
- Clinical features and outcomes of patients with myositis associated-interstitial lung disease.Frontiers in medicine · 2022Article
- Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study.Respiratory research · 2021Article
- Infliximab-induced interstitial lung disease.BMJ case reports · 2021Article
- Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment.BMC pulmonary medicine · 2020Article
- Prevalence of Novel Myositis Autoantibodies in a Large Cohort of Patients with Interstitial Lung Disease.Journal of clinical medicine · 2020Article
- False Positive COVID-19 Antibody Test in a Case of Granulomatosis With Polyangiitis.Frontiers in medicine · 2020Article
- Pirfenidone in idiopathic pulmonary fibrosis: real-life experience in the referral centre of Siena.Therapeutic advances in respiratory diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung diseases (ILD) represent a group of heterogeneous parenchymal lung disorders with complex pathophysiology, characterized by different clinical and radiological patterns, ultimately leading to pulmonary fibrosis. A considerable proportion of these disease entities present with no effective treatment, as current therapeutic regimens only slow down disease progression, thus leaving patients, at best case, with considerable functional disability. Biologic therapies have emerged and are being investigated in patients with different forms of ILD. Unfortunately, their safety profile has raised many concerns, as evidence shows that they might cause or exacerbate ILD status in a subgroup of patients. This review article aims to summarize the current state of knowledge on their role in patients with ILD and highlight future perspectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.